Premium
Prevention of hepatitis B virus recurrence after liver transplantation
Author(s) -
Eisenbach Christoph,
Sauer Peter,
Mehrabi Arianeb,
Stremmel Wolfgang,
Encke Jens
Publication year - 2006
Publication title -
clinical transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 76
eISSN - 1399-0012
pISSN - 0902-0063
DOI - 10.1111/j.1399-0012.2006.00609.x
Subject(s) - lamivudine , adefovir , medicine , liver transplantation , hepatitis b virus , hepatitis b immune globulin , hepatitis b , transplantation , emtricitabine , virology , nucleoside analogue , liver disease , gastroenterology , virus , nucleoside , biology , biochemistry
Liver transplantation for hepatitis B virus (HBV)‐related liver disease has changed from a contraindication to outcomes comparable with non‐HBV‐related liver transplantations during the last two decades. Mainly the implementation of immunoprophylaxis with hepatitis B immunoglobulin (HBIG) and the use of nucleoside analogs such as lamivudine and adefovir account for this dramatic change. The standard of care in most centers today consists of lamivudine treatment in replicating hepatitis B pre‐orthotopic liver transplantation (OLT) and a combination regimen of lamivudine and HBIG post‐OLT. With adefovir, a potent antiviral drug became available in recent years that allows for the treatment of patients with lamivudine‐resistant tyrosine‐methionine‐aspartate‐aspartate (YMDD)‐mutant HBV. In the transplantation setting, first studies indicate that a triple prophylactic therapy consisting of lamivudine, adefovir, and HBIG will become the standard of care for YMDD‐mutant‐related hepatitis B. With new drugs emerging for the treatment of chronic HBV, there is optimism for new options also in the transplant setting.